Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,055,754
  • Shares Outstanding, K 66,949
  • Annual Sales, $ 271,030 K
  • Annual Income, $ -186,570 K
  • 60-Month Beta 1.95
  • Price/Sales 26.86
  • Price/Cash Flow N/A
  • Price/Book 5.79
Trade RARE with:

Options Overview

Details
  • Implied Volatility 69.23%
  • Historical Volatility 46.25%
  • IV Percentile 44%
  • IV Rank 40.87%
  • IV High 91.44% on 07/27/20
  • IV Low 53.87% on 02/17/21
  • Put/Call Vol Ratio 5.00
  • Today's Volume 18
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 5,630
  • Open Int (30-Day) 2,486

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -1.24
  • Number of Estimates 10
  • High Estimate -0.93
  • Low Estimate -1.80
  • Prior Year -2.04
  • Growth Rate Est. (year over year) +39.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.61 +5.40%
on 04/12/21
126.27 -16.85%
on 03/22/21
-19.74 (-15.83%)
since 03/19/21
3-Month
99.61 +5.40%
on 04/12/21
175.00 -40.01%
on 02/10/21
-30.16 (-22.32%)
since 01/20/21
52-Week
57.10 +83.87%
on 05/01/20
179.65 -41.56%
on 12/24/20
+41.89 (+66.39%)
since 04/20/20

Most Recent Stories

More News
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases

n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, today announced a new partnership...

RARE : 104.99 (-0.38%)
Ultragenyx Pharm Has Returned 15.4% Since SmarTrend Recommendation (RARE)

SmarTrend identified a Downtrend for Ultragenyx Pharm (NASDAQ:RARE) on February 16th, 2021 at $147.89. In approximately 1 month, Ultragenyx Pharm has returned 15.45% as of today's recent price of $125.04....

RARE : 104.99 (-0.38%)
Why Is Ultragenyx (RARE) Down 22% Since Last Earnings Report?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RARE : 104.99 (-0.38%)
Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA

The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.

RGEN : 211.99 (-0.02%)
ARCT : 36.64 (-0.73%)
RARE : 104.99 (-0.38%)
STOK : 31.16 (+2.03%)
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced...

RARE : 104.99 (-0.38%)
Ultragenyx to Present at Barclays Global Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced...

RARE : 104.99 (-0.38%)
Ultragenyx to Present at Upcoming Investor Conferences

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced...

RARE : 104.99 (-0.38%)
Ultragenyx Announces Approval of Dojolvi(TM) (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced...

RARE : 104.99 (-0.38%)
Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates

Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.

ALXN : 166.54 (+0.65%)
ACOR : 4.15 (-1.43%)
RARE : 104.99 (-0.38%)
AVIR : 42.34 (-4.85%)
Ultragenyx: 4Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $24 million in its fourth quarter.

RARE : 104.99 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

3rd Resistance Point 114.78
2nd Resistance Point 111.67
1st Resistance Point 108.33
Last Price 104.99
1st Support Level 101.88
2nd Support Level 98.77
3rd Support Level 95.43

See More

52-Week High 179.65
Fibonacci 61.8% 132.83
Fibonacci 50% 118.37
Last Price 104.99
Fibonacci 38.2% 103.91
52-Week Low 57.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar